[{"orgOrder":0,"company":"Merck Group","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pimasertib","moa":"||MEK1\/2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Merck Group \/ Day One Biopharmaceuticals"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"||Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovorafenib","moa":"||Type II Pan-RAF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Day One Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Biopharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Pimasertib (AS-703026)

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ASCO Annual meeting
                          Not Confirmed
                          ASCO Annual meeting
                          Not Confirmed

                          Details : DAY101 (Tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of...

                          Product Name : Ojemda

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 23, 2022

                          Lead Product(s) : Tovorafenib,Pimasertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ASCO Annual meeting
                          Not Confirmed
                          ASCO Annual meeting
                          Not Confirmed

                          Details : DAY101 has demonstrated encouraging anti-tumor activity as a monotherapy in patient populations where MAPK pathway alterations are believed to play an important role in driving disease progression.

                          Product Name : Ojemda

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 22, 2021

                          Lead Product(s) : Tovorafenib,Pimasertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ASCO Annual meeting
                          Not Confirmed
                          ASCO Annual meeting
                          Not Confirmed

                          Details : Exclusive license agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of pimasertib and MSC2015103B. Day One plans to study the combination of pimasertib and DAY101 in patients ≥12 years of age with ad...

                          Product Name : MSC19363639B

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 23, 2021

                          Lead Product(s) : Pimasertib,Tovorafenib

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Day One Biopharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank